Impilo AB, established in 2017, is a Stockholm-based private equity firm with an additional office in Copenhagen, Denmark. It specializes in buyout and growth capital investments in the healthcare sector, focusing on pharmaceuticals, medical technology, medical devices, care services, and preventative care segments. Impilo primarily targets unlisted companies in the Nordic region with revenues between SEK 200 million and SEK 1.5 billion, investing between SEK 100 million and SEK 1 billion. The firm prefers majority stakes but can also take minority positions, and it considers both public and private investments if a controlling position is available. Impilo's investment strategy aims to contribute positively to the communities and markets in which its portfolio companies operate, fostering long-term success.
Co-Founder, Partner and Investment Committee Member
Sören Mellstig
Co-Founder
Victor Steien
Partner
Fredrik Strömholm
Co-Founder, Partner and Chairman of the Investment Committee
Henning Søgaard
Industrial Partner
Frederik Zimmer
Industrial Partner
Magnus Edlund
Partner
7 past transactions
Qufora
Acquisition in 2024
Qufora is a medical device company focused on developing solutions for individuals with chronic bowel disorders. The company specializes in products that facilitate bowel irrigation and address issues such as chronic constipation and fecal incontinence. By providing innovative medical irrigation solutions, Qufora aims to improve the quality of life for those suffering from these conditions.
Immedica
Private Equity Round in 2024
Immedica is a fast-growing private niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has commercial coverage across Europe and the Middle East. Immedica provides significant know-how and experience from the commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access to specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality, and product distribution. Immedica’s main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 3.6 billion in committed capital from leading Nordic and international investors.
VaccinDirekt
Acquisition in 2023
VaccinDirekt operates a network of vaccination clinics throughout Sweden, focusing on a range of medical services. The company provides vaccinations, travel medicine, health checks, and certifications for both infants and adults. In addition to these services, VaccinDirekt offers up-to-date health advice and consultations. Clients can reach the company through various contact methods, including mail, phone, and in-person visits.
Pelago Bioscience
Venture Round in 2023
Pelago Bioscience specializes in drug discovery through its innovative Cellular Thermal Shift Assay technology. This approach facilitates target engagement studies that analyze how drug candidates interact with specific target proteins within cells and tissues. By providing more relevant data for drug delivery, the company's technology enhances the ability to filter compounds based on physiologically relevant information. This capability aids in bridging the gap between laboratory research and clinical application, ultimately leading to the faster and more effective development of new and improved therapeutics.
Decon
Acquisition in 2023
Decon is a manufacturer and supplier of medical equipment as well as accessories for all types of wheelchairs in the market.
Scantox
Acquisition in 2021
Scantox is a contract research organization located in Lille Skensved, Denmark, specializing in pharmacology and regulatory toxicology services. The company provides preclinical research services tailored for the pharmaceutical and medical device industries, assisting clients in advancing their drug or device development with reliable data that meets technical and scientific standards. Scantox offers a range of services, including safety pharmacology, exploratory testing, and endotoxin testing, ensuring comprehensive support throughout the product development process.
Cavidi
Venture Round in 2018
Cavidi AB is a Swedish biotech company specializing in viral load solutions for monitoring human immunodeficiency virus (HIV). Founded in 1984 as a spin-off from Uppsala University, Cavidi develops products such as the ZIVA Viral Load system, designed for medium throughput in district hospitals, and the ExaVIR Load, a near-patient monitoring solution. The company also provides the ExaVIR drug for HIV treatment, as well as research tools like reverse transcriptase activity kits and viral titer measurement services. By offering efficient diagnostics, Cavidi supports the management of antiretroviral therapy, helping patients with HIV to maintain a normal lifespan while reducing treatment costs and the spread of the virus. The company's clientele includes hospitals, patient clinics, private laboratories, the pharmaceutical industry, and research institutions globally. Cavidi is headquartered in Uppsala, Sweden, with additional sales offices in South Africa, India, and the United States.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.